Table 1.
Clinical and laboratory characteristics of the 100 allotransplant recipients included in the study.
| Age, Median and Range (Years) | 47.5 (15–70) |
|---|---|
| Caucasian/non-Caucasian (number) | 95/5 |
| Diagnosis (number) | |
| AML | 43 |
| MDS-AML | 16 |
| Myelodysplastic syndrome (MDS), high-risk | 4 |
| Acute lymphoblastic leukemia | 20 |
| Chronic myeloid leukemia | 2 |
| Myelofibrosis | 4 |
| Chronic myelomonocytic leukemia | 2 |
| Myeloproliferative neoplasia, unspecified | 2 |
| Aplastic anemia | 4 |
| Chronic lymphocytic leukemia | 2 |
| Hodgkin’s lymphoma | 1 |
| Remission at transplantation (number) | 99 |
| aGVHD requiring high dose steroid treatment (number) 1 | 46 |
| Conditioning regimes (number) | |
| Busulfan + cyclophosphamide (myeloablative condition) | 74 |
| Fludarabine + busulfan (reduced intensity conditioning) | 17 |
| Antithymocyte globulin + cyclophosphamide | 4 |
| Others | 5 |
| GVHD prophylaxis (number) | |
| Cyclosporine A + methotrexate | 97 |
| Cyclosporine A + mycophenolate mofetil | 1 |
| Cyclosporine A + methotrexate + antithymocyte globulin | 2 |
| Donor (number) | |
| Related | 100 |
| Sibling | 93 |
| Parent | 6 |
| Other related | 1 |
| Female/male donor | 39/61 |
| Female donor to male recipient | 21 |
| CMV pos. recipient | 65 |
| CMV pos. donor to neg. recipient | 18 |
| Stem cell source (number) | |
| Bone marrow grafts | 5 |
| G-CSF mobilized peripheral blood stem cell grafts | 95 |
| CRP mg/L (median and range; lower limit of detection being 1.0 mg/L) | 5 (<1–120) |
| Maximum weight gain kg (median, range) | 5.0 (0–16.1) |
1 The criteria for high-dose steroid treatment were acute GVHD grade II with gastrointestinal involvement or Grade III/IV acute GVHD.